There is no other single conference where so much information is presented about myeloma. Information about so many topics is provided:  how to treat MM patients in various stages; results of phase II & III trials which may indicate upcoming FDA approvals; pre-clinical research focusing on myeloma targets and cell understanding; and more. However, this year […]